GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alimera Sciences Inc (NAS:ALIM) » Definitions » Interest Coverage

Alimera Sciences (Alimera Sciences) Interest Coverage : 0 (At Loss) (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Alimera Sciences Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Alimera Sciences's Operating Income for the three months ended in Mar. 2024 was $-2.30 Mil. Alimera Sciences's Interest Expense for the three months ended in Mar. 2024 was $-3.74 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Alimera Sciences's Interest Coverage or its related term are showing as below:


ALIM's Interest Coverage is not ranked *
in the Drug Manufacturers industry.
Industry Median: 12.275
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Alimera Sciences Interest Coverage Historical Data

The historical data trend for Alimera Sciences's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Alimera Sciences Interest Coverage Chart

Alimera Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alimera Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.90 0.15 -

Competitive Comparison of Alimera Sciences's Interest Coverage

For the Drug Manufacturers - Specialty & Generic subindustry, Alimera Sciences's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alimera Sciences's Interest Coverage Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alimera Sciences's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Alimera Sciences's Interest Coverage falls into.



Alimera Sciences Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Alimera Sciences's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Alimera Sciences's Interest Expense was $-10.19 Mil. Its Operating Income was $-1.93 Mil. And its Long-Term Debt & Capital Lease Obligation was $64.49 Mil.

Alimera Sciences did not have earnings to cover the interest expense.

Alimera Sciences's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Here, for the three months ended in Mar. 2024, Alimera Sciences's Interest Expense was $-3.74 Mil. Its Operating Income was $-2.30 Mil. And its Long-Term Debt & Capital Lease Obligation was $69.44 Mil.

Alimera Sciences did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Alimera Sciences  (NAS:ALIM) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Alimera Sciences Interest Coverage Related Terms

Thank you for viewing the detailed overview of Alimera Sciences's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Alimera Sciences (Alimera Sciences) Business Description

Traded in Other Exchanges
Address
6310 Town Square, Suite 400, Alpharetta, GA, USA, 30005
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.
Executives
Margaret Pax director 6310 TOWN SQUARE, SUITE 400, ALPHARETTA GA 30005
John Snisarenko director C/O ALIMERA SCIENCES, INC., 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Pizzo Peter J. Iii director 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Erin Parsons director 97 WILLISTON RD, BROOKLINE MA 02445
Caligan Partners Lp 10 percent owner 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Ross D Demont director 51 PICKWICK ROAD, NEWTON MA 02465
C. Daniel Myers other: Chairman Emeritus 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
David Edward Johnson 10 percent owner 590 MADISON AVENUE, NEW YORK NY 10022
Velan Capital Master Fund Lp 10 percent owner 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Management Llc 10 percent owner 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Holdings Llc 10 percent owner 1055B POWERS PLACE, ALPHARETTA GA 30009
Adam Morgan director 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Investment Management Lp 10 percent owner 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Spv I Llc 10 percent owner 1055B POWERS PLACE, ALPHARETTA GA 30009
Balaji Venkataraman 10 percent owner FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076